Skip to main content

Table 3 Biodistribution (1 MBq/0.3 or 3.0 nmol) of 177 Lu-DOTA-PEG 5k -Lys-BN analogue in nude mice bearing PC-3 tumours

From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues

  177Lu-DOTA-PEG 5k-Lys-BN
  1 h p.i. 24 h p.i.
Tissue 0.3 nmol 3.0 nmol 0.3 nmol 3.0 nmol
Blood 0.51 ± 0.09 0.77 ± 0.11* 0.02 ± 0.00 0.02 ± 0.00
Heart 0.22 ± 0.05 0.31 ± 0.09 0.04 ± 0.01 0.05 ± 0.01
Lung 0.92 ± 0.59 2.03 ± 1.64 0.44 ± 0.32 0.58 ± 0.36
Spleen 0.45 ± 0.11 0.39 ± 0.05 0.40 ± 0.06 0.21 ± 0.04
Kidneys 3.11 ± 0.42 3.92 ± 0.59 1.59 ± 0.42 2.12 ± 0.21
Pancreas 4.65 ± 0.18** 1.45 ± 0.18 3.72 ± 0.98* 0.90 ± 0.26
Stomach 0.42 ± 0.09 0.89 ± 0.65 0.16 ± 0.03 0.14 ± 0.10
Small intestine 0.55 ± 0.02 0.78 ± 0.39 0.20 ± 0.04* 0.10 ± 0.02
Colon 0.79 ± 0.14 0.59 ± 0.10 0.31 ± 0.08* 0.11 ± 0.03
Liver 0.50 ± 0.06 0.64 ± 0.07 0.51 ± 0.05 0.46 ± 0.02
Muscle 0.17 ± 0.03 0.20 ± 0.05 0.02 ± 0.01 0.02 ± 0.00
Bone 0.21 ± 0.03 0.31 ± 0.03 0.23 ± 0.03 0.22 ± 0.03
Tumour 2.06 ± 0.41* 1.47 ± 0.42 1.14 ± 0.10 0.66 ± 0.26
Tumour-to-blood 4.08 ± 0.54 1.89 ± 0.42 62.46 ± 3.58 36.24 ± 13.73
Tumour-to-liver 4.11 ± 0.67 2.28 ± 0.60 2.78 ± 0.21 1.47 ± 0.56
Tumour-to-kidney 0.67 ± 0.14 0.38 ± 0.13 0.62 ± 0.07 0.33 ± 0.16
Tumour-to-muscle 12.26 ± 4.01 7.20 ± 0.90 55.89 ± 32.86 27.27 ± 11.92
Tumour-to-pancreas 0.44 ± 0.08 1.01 ± 0.23 0.28 ± 0.08 0.62 ± 0.22
  1. *P < 0.05.; **P < 0.001. Data in percentage of injected dose per gram of tissue (%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n = 3).